出品:新浪财经上市公司研究院作者:天利近日,复星医药发布了2024年财报。数据显示,报告期内,公司实现营业收入410.67亿元,同比下降0.80%;归属于母公司股东的净利润为27.70亿元,同比增长16.08%。结合往期数据来看,公司营收已连续两年出现同比下滑,利润端在去年低基数的背景下有所改善,但仍处于历史较低水平,过去十年间仅高于2015年、2018年。抗肿瘤业务营收增速骤降 利润增长16%...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.